When can immunotherapy for insect sting allergy be stopped?

Area of Science:

• Allergy and Immunology
• Toxicology

Background:

• Hymenoptera stings (bees, wasps, ants) can trigger severe systemic allergic reactions (SARs).
• Venom immunotherapy (VIT) significantly reduces the risk of recurrent SARs, with effectiveness increasing with treatment duration.

Purpose of the Study:

• To review risk factors for recurrent SARs after discontinuing VIT.
• To provide evidence-based recommendations for VIT duration and management post-treatment.

Main Methods:

• Review of identified risk factors for recurrent SARs.
• Discussion of recommendations for stopping VIT based on risk factor assessment.

Main Results:

• For patients without risk factors, VIT should extend to 5 years (vs. 3).
• Patients with risk factors require extended VIT discussion; lifelong VIT is recommended for mast cell disorders.
• A residual risk of SARs necessitates indefinite epinephrine autoinjector use and sting avoidance.

Conclusions:

• Optimizing VIT duration based on individual risk factors is crucial for preventing recurrent SARs.
• Long-term management strategies, including autoinjector use, are essential even after successful VIT.